ArticleCureus2026
Rapid Resolution of Apophenic Psychosis With Low-Dose Olanzapine in Very Late-Onset Schizophrenia-Like Psychosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Very late‑onset schizophrenia‑like psychosis (VLOSLP) presents diagnostic complexity due to the broad range of medical, neurological, and psychiatric conditions that can manifest with late‑life psychosis. We describe a case of a man in his mid‑70s who developed progressive apophenic experiences, characterised by the perception of patterns, rhythms, and "algorithms" in everyday environments, leading to referential beliefs and behavioural change. Investigations showed normal blood tests, preserved cognitive screening scores, and MRI evidence of chronic white matter ischaemic changes and diffuse cerebral atrophy. Differential diagnoses included vascular psychosis, autoimmune encephalitis, obsessive-compulsive disorder with poor insight, and neurodegenerative disease; however, the overall presentation was most consistent with VLOSLP. The patient was treated using a bio‑psycho‑social approach, with limited response to quetiapine but rapid and sustained remission following initiation of low‑dose olanzapine. Symptom recurrence after dose reduction further supported a primary psychotic process. This case highlights an atypical presentation of VLOSLP dominated by apophenia and underscores the importance of thorough assessment and cautious, individualised antipsychotic treatment in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.